Yuhan said on the 11th that operating profit under consolidation last year was tentatively tallied at 104.3 billion won, up 90.2% from a year earlier. Revenue for the same period rose 5.7% to 2.1866 trillion won.
The company cited increased sales in the pharmaceuticals business, overseas operations, and subsidiaries as the backdrop for the results.
As drivers of operating profit growth, it pointed to a higher proportion of product sales and an improved cost ratio. As reasons for the increase in net income, it cited higher gains on the disposal of equity-method investment shares, among other factors.
A Yuhan official said, "In the fourth quarter, robust growth in the core pharmaceuticals business and receipt of milestone payments tied to the development stage through the commercialization in China of the combination therapy for the lung cancer drug 'Leclaza' led, on a separate basis, to a 53.5 billion won increase in revenue and a 31.8 billion won increase in operating profit from a year earlier."